From: A comparative study between effect of combined intravenous and nebulized amikacin versus intravenous amikacin alone in mechanically ventilated patients with ventilator-associated pneumonia (VAP)
Group A
Group B
A/B^
Duration MV
Median (IQR)
19.0
(16.0–26.3)
23.5
(21.3–26.0)
0.037*
Range
13.0–90.0
20.0–38.0
LOS
21.5
(16.3–27.0)
25.5
(23.0–28.5)
0.045*
15.0–90.0